TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomize
Clinicaltrials.gov identifier: NCT04325763. Date of registration: May 27, 2020. Protocol version: Version 4.0, Sep 16, 2022 (https://classic.clinicaltrials.gov/ct2/show/NCT04325763).
Authors
- Xuan Zhu (ORCID: https://orcid.org/0000-0003-1581-9767)
- Ou Jiang (ORCID: https://orcid.org/0000-0002-3455-9676)
- Xiangjiao Meng (ORCID: https://orcid.org/0000-0001-7380-5510)
- Qiuyue Cao
- Xunqiang Wang
- Baiqiang Dong (ORCID: https://orcid.org/0000-0003-4867-9086)
- Rongrong Zhou
- Long Chen (ORCID: https://orcid.org/0000-0002-7347-3074)
- Jie Li (ORCID: https://orcid.org/0000-0002-4433-5393)
- Ming Chen (ORCID: https://orcid.org/0000-0003-2570-0858)
- Yufeng Cheng (ORCID: https://orcid.org/0000-0002-4143-5399)
- Yongling Ji
- Hong Ge (ORCID: https://orcid.org/0000-0001-8456-3852)
- Qingsong Pang
Institutions
- Central South University (CN)
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Shandong Tumor Hospital (CN)
- Shanxi Provincial Cancer Hospital (CN)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Xiangya Hospital Central South University (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-362
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42